A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-07 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The mean lifetime of 238U (or any nuclide) is the half-life divided by ln(2) ≈ 0.693 (or multiplied by 1/ln(2) ≈ 1.443), which is about 2×1017 seconds, so 1 mole of 238U emits 3×106 alpha particles per second, producing the same number of thorium-234 atoms. In a closed system an equilibrium would be reached in which all members except the stable end-product have fixed ratios to one another, but in slowly decreasing amount. The amount of 206Pb will increase accordingly while that of 238U decreases; all steps in the decay chain have this same rate of 3×106 decayed particles per second per mole 238U. While 238U is minimally radioactive, its decay products, thorium-234 and protactinium-234, are beta particle emitters with half-lives of about 20 days and one minute respectively. Protactinium-234 decays to uranium-234, which has a half-life of hundreds of millennia, and this isotope does not reach an equilibrium concentration for a very long time. When the two first isotopes in the decay chain reach their relatively small equilibrium concentrations, a sample of initially pure 238U will emit three times the radiation due to 238U itself, and most of this radiation is beta particles. As already touched upon above, when starting with pure 238U, within a human timescale the equilibrium applies for the first three steps in the decay chain only. Thus, for one mole of 238U, 3×106 times per second one alpha and two beta particles and a gamma ray are produced, together 6.7 MeV, for a rate of 3 μW.
Distinguishing features of Thomas's early poetry include its verbal density, use of alliteration, sprung rhythm and internal rhyme, with some critics detecting the influence of the English poet Gerard Manley Hopkins. Walford Davies suggests there is little else than "a coincidence of poetic temperament." Thomas himself wrote to Henry Treece, who had compared the two, denying any significant influence. Thomas also employed fixed verse form, such as in the villanelle "Do not go gentle into that good night". Thomas greatly admired Thomas Hardy, who is regarded as an influence. When Thomas travelled in America, he recited some of Hardy's work in his readings. Other poets from whom critics believe Thomas drew influence include James Joyce, Arthur Rimbaud and D. H. Lawrence. William York Tindall, in his 1962 study, A Reader's Guide to Dylan Thomas, finds comparison between Thomas's and Joyce's wordplay, while he notes the themes of rebirth and nature are common to the works of Lawrence and Thomas. Although Thomas described himself as the "Rimbaud of Cwmdonkin Drive", he stated that the phrase "Swansea's Rimbaud" was coined by poet Roy Campbell. Critics have explored the origins of Thomas's mythological pasts in his works such as "The Orchards", which Ann Elizabeth Mayer believes reflects the Welsh myths of the Mabinogion. Thomas's poetry is notable for its musicality, most clear in "Fern Hill", "In Country Sleep", "Ballad of the Long-legged Bait" and "In the White Giant's Thigh".
== Bibliography == Brock, Sebastian P. (1987). "North Mesopotamia in the late Seventh Century: Book XV of John Bar Penkāyē's Rīš Mellē". Jerusalem Studies in Arabic and Islam. 9: 51–75. ISSN 0334-4118. Crone, Patricia (1980). Slaves on Horses: The Evolution of the Islamic Polity (1980 ed.). Cambridge: Cambridge University Press. p. 93. ISBN 978-0521229616. Donner, Fred M. (2010). Muhammad and the Believers. Cambridge: The Belknap Press of Harvard University Press. ISBN 978-0-674-05097-6. Gibb, H. A. R. (2013) [1923]. The Arab Conquests in Central Asia. Read Books. ISBN 1-4067-5239-8. Gibb, H. A. R. (2007). The Arab Conquests in Central Asia. Read Books. ISBN 978-1-4067-5239-7. reprinted from the 1923 edition, published by the Royal Asiatic Society OCLC 474026895. Hasson, I. (2002). "Ziyād b. Abiḥī". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E.; Heinrichs, W. P. (eds.). The Encyclopedia of Islam. Vol. XI: W–Z (new ed.). Leiden and New York: Brill. pp. 519–522. ISBN 90-04-12756-9. Kennedy, Hugh (2001). The Armies of the Caliphs: Military and Society in the Early Islamic State. London and New York: Routledge. ISBN 0-415-25093-5. Kennedy, Hugh (2004) [1986]. The Prophet and the Age of the Caliphates: The Islamic Near East from the 6th to the 11th Century (Second ed.). Harlow: Longman. ISBN 978-0-582-40525-7. Madelung, Wifred (October 1981). "ʿAbd Allāh b. al-Zubayr and the Mahdi". Journal of Near Eastern Studies. 4 (1): 291–305. ISSN 0022-2968. JSTOR 544603. Robinson, C. F. (2000). "ʿUbayd Allāh b. Ziyād". In Bearman, P. J.; Bianquis, Th.; Bosworth, C.
=== Conductors === According to Gauss’s law, a conductor at equilibrium carrying an applied current has no charge on its interior. Instead, the entirety of the charge of the conductor resides on the surface, and can be expressed by the equation:
Sources: en.wikipedia.org
==== Establishment and growth ==== In the first half of the 1st century AD, acupuncturists began promoting the belief that acupuncture's effectiveness was influenced by the time of day or night, the lunar cycle, and the season. The 'science of the yin-yang cycles' (運氣學 yùn qì xué) was a set of beliefs that curing diseases relied on the alignment of both heavenly (tian) and earthly (di) forces that were attuned to cycles like that of the sun and moon. There were several different belief systems that relied on a number of celestial and earthly bodies or elements that rotated and only became aligned at certain times. According to Needham and Lu, these "arbitrary predictions" were depicted by acupuncturists in complex charts and through a set of special terminology. Acupuncture needles during this period were much thicker than most modern ones and often resulted in infection. Infection is caused by a lack of sterilization, but at that time it was believed to be caused by use of the wrong needle, or needling in the wrong place, or at the wrong time. Later, many needles were heated in boiling water, or in a flame. Sometimes needles were used while they were still hot, creating a cauterizing effect at the injection site. Nine needles were recommended in the Great Compendium of Acupuncture and Moxibustion from 1601, which may have been because of an ancient Chinese belief that nine was a magic number. Other belief systems were based on the idea that the human body operated on a rhythm and acupuncture had to be applied at the right point in the rhythm to be effective.
Distal axonopathy, is the result of interrupted function of the peripheral nerves. It is the most common response of neurons to metabolic or toxic disturbances, and may be caused by metabolic diseases such as diabetes, kidney failure, connective tissue disease, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs such as chemotherapy. They may be divided according to the type of axon affected (large-fiber, small-fiber, or both). The most distal portions of axons are usually the first to degenerate, and axonal atrophy advances slowly toward the nerve's cell body. However, if the cause is removed, then regeneration is possible, although the prognosis depends on the duration and severity of the original stimulus. People with distal axonopathies usually present with sensorimotor disturbances such as amyotrophic lateral sclerosis. Myelinopathy, is due to a loss of myelin or of the Schwann cells. This demyelination slows down or completely blocks the conduction of action potentials through the axon of the nerve cell (neurapraxia). The most common cause is acute inflammatory demyelinating polyneuropathy AIDP, the most common form of Guillain–Barré syndrome (although other causes include chronic inflammatory demyelinating polyneuropathy). Neuronopathy is the result of issues in the peripheral nervous system (PNS) neurons. They may be caused by motor neurone diseases, sensory neuronopathies, toxins, or autonomic dysfunction. Neurotoxins such as chemotherapy agents may cause neuronopathies.
== Animal tissue == Animal tissues are grouped into four basic types: connective, muscle, nervous, and epithelial. Organs are formed by the functional grouping together of two or more different tissue types. While most animals can generally be considered to contain the four tissue types, the manifestation of these tissues can differ depending on the type of organism. For example, the origin of the cells comprising a particular tissue type may differ developmentally for different classifications of animals. Tissue appeared for the first time in the diploblasts, but modern forms only appeared in triploblasts. The epithelium in all animals is derived from the ectoderm and endoderm (or their precursor in sponges), with a small contribution from the mesoderm, forming the endothelium, a specialized type of epithelium that composes the vasculature. By contrast, a true epithelial tissue is present only in a single layer of cells held together via occluding junctions called tight junctions, to create a selectively permeable barrier. This tissue covers all organismal surfaces that come in contact with the external environment such as the skin, the airways, and the digestive tract. It serves functions of protection, secretion, and absorption, and is separated from other tissues below by a basal lamina. The connective tissue and the muscular are derived from the mesoderm. The nervous tissue is derived from the ectoderm.
=== Australia and New Zealand === Mitragyna speciosa is a prohibited substance in Australia. In New Zealand, Mitragyna speciosa is designated a prescription medicine, and its use in herbal remedies is prohibited under section 2 of the Medicines Act 1981.
== Speech at the Ceremony Marking the 65th Anniversary of the Basic Law, Germany’s Constitution (2014) == On May 23, 2014, the German Parliament Bundestag held a ceremony commemorating the proclamation of the Basic Law on May 23, 1949. Kermani was invited as the keynote speaker. In his speech, he analyzed the language of the Basic Law, comparing its impact to that of the Luther Bible. Kermani discussed the historic progress made in the postwar period and noted that the Basic Law had created a new reality. Kermani praised the Federal Republic of Germany for upholding constitutional norms. He also commended German society for its willingness to bring about integration and its efforts in this regard. He mentioned Willy Brandt several times. Referring to Brandt, Kermani noted, “If I were to name a single day, a single event, a single gesture in postwar German history for which the word ‘dignity’ seems appropriate, (…) it would be Brandt’s kneeling in Warsaw.” Kermani sharply criticized the restriction of the right to asylum through the 1993 amendment to the Basic Law (asylum compromise), which he described as a distortion of Article 16a and a mutilation of the Constitution. Nevertheless, he emphasized the opportunities that the Federal Republic of Germany has offered immigrants. He concluded his speech—on their behalf—with the words Thank you, Germany. Some members of the CDU/CSU parliamentary group criticized the speech as one-sided or biased; Georg Nüßlein (CSU) left the chamber. In the German media, however, the speech was well received and positively discussed.
Sources: en.wikipedia.org
== Application == One application of FAIMS is as an additional separation step between the liquid chromatography separation and mass spectrometric analysis in liquid chromatography–mass spectrometry (LC-MS) as used in proteomic studies. It allows for online fractionation of the analyte components to improve detection of peptides in complex samples. LC-MS uses the mass to charge ratio of peptide ions to analyse samples and the resulting spectra are compared to spectral reference libraries. FAIMS can be used to filter out "chemical noise", i.e. compounds whose spectra would interfere with the spectra of the desired compound, either by overlapping with the desired compound's spectra or adding additional peaks to the spectra. It can be used to filter out interfering ions and simultaneously select peptides with charge states that are optimal for analysis. A further advantage of this technique is that it can be used to select for peptide ions that are of low abundance in the sample. Such low abundance ions are often not analysed because of the limitations of the duty cycles of the mass spectrometers. By selectively removing the more abundant ions FAIMS can assist in distinguishing between ions with similar mass to charge ratios and can prevent a more abundant ion from masking the presence of a less abundant ion.
The report concluded that a final determination of the origin was unlikely without cooperation from the Chinese government, saying their prior lack of transparency "reflect[ed] in part China's government's own uncertainty about where an investigation could lead, as well as its frustration that the international community is using the issue to exert political pressure on China." Chinese foreign ministry spokesman Wang Wenbin said that the US intelligence report was "unscientific and has no credibility". On 23 May 2021, The Wall Street Journal reported that a previously undisclosed US intelligence report stated that three researchers from the Wuhan Institute of Virology became ill enough in November 2019 to seek hospital care. The report did not specify what the illness was. Officials familiar with the intelligence differed as to the strength to which it corroborates the hypothesis that the virus responsible for COVID-19 was leaked from the WIV. The WSJ report notes that it is not unusual for people in China to go to the hospital with uncomplicated influenza or common cold symptoms. Yuan Zhiming, director of the WIV's Wuhan National Biosafety Laboratory, responded in the Global Times, a Chinese state media outlet, that the "claims are groundless". Marion Koopmans, a member of the WHO study team, described the number of flu-like illnesses at the WIV in 2019 as "completely normal". Workers at the WIV must provide yearly serum samples. WIV virologist Shi Zhengli said in 2020 that, based on an evaluation of those serum samples, all staff tested negative for COVID-19 antibodies.
== Production == Aerated chocolate containing large bubbles is produced via two methods. In the first, melted chocolate is put under a vacuum, where it foams up. As the chocolate cools, and the fats within the chocolate set, the foam structure remains. Sometimes gases such as carbon dioxide are introduced into the mixture before it is placed under the vacuum. Although the method easily permits inclusions such as nougat or nuts, the production is labor-intensive and difficult to keep hygienic. As a result, the second method is more frequently used: working gases into liquid, tempered chocolate under high pressure. Carbon dioxide is mainly used, although others include nitrous oxide. Air is avoided, as oxygen causes chocolate to become rancid. Any gases that do not dissolve are dispersed as bubbles through the chocolate using a beater. As the chocolate is released from the high pressure conditions, the bubbles expand, foaming the product; through this, the amount of pressure directly impacts bubble size. The setting chocolate is deposited in a moulded shell, after which the set interior is capped with liquid tempered chocolate. Factors that affect bubble size include qualities of chocolate, such as viscosity and the rate of setting. The ingredients used, such as emulsifiers and milk fats also impact bubble size; other factors include type of gas and how much pressure is applied. Micro-aerated chocolate is created using the method of beating gases in under high pressure.
== Stanford Research Institute == In 1962, Finnigan and one of his coworkers, physicist and nuclear engineer P. Michael Uthe Jr., left Livermore to work for the Stanford Research Institute (SRI) in Palo Alto, California. Finnigan was hired to establish a process controls group in SRI's control systems lab. SRI did contract research projects for both business and the military. One of the projects underway at SRI, led by Kenneth R. Shoulders, was developing a quadrupole mass spectrometer. Finnigan saw the potential for using the quadrupole broadly as a detector for instrumentation and process-control, and began trying to find support for its development and commercialization.
Although contradictory reports exist, one study found mean integrated estradiol levels of 150 pg/mL in younger women whereas mean integrated levels ranged from 50 to 120 pg/mL in older women. During the reproductive years of human females, levels of estradiol are somewhat higher than that of estrone, except during the early follicular phase of the menstrual cycle; thus, estradiol may be considered the predominant estrogen during human female reproductive years in terms of absolute serum levels and estrogenic activity. During pregnancy, estriol becomes the predominant circulating estrogen, and this is the only time at which estetrol occurs in the body, while during menopause, estrone predominates (both based on serum levels). The estradiol produced by male humans, from testosterone, is present at serum levels roughly comparable to those of postmenopausal women (14–55 versus <35 pg/mL, respectively). It has also been reported that if concentrations of estradiol in a 70-year-old man are compared to those of a 70-year-old woman, levels are approximately 2- to 4-fold higher in the man.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.